{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:59:23Z","timestamp":1784383163638,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,23]]},"DOI":"10.7759\/cureus.97530","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T08:01:21Z","timestamp":1763884881000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Akinori","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa GK","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al.. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022, 1:EVIDoa2100070. 10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau T","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, et al.. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025, 405:1851-64. 10.1016\/S0140-6736(25)00403-9","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review","volume":"11","author":"Kitagawa S","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020, 11:1927-33. 10.1111\/1759-7714.13483","journal-title":"Thorac Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.75724","article-title":"Exceptional response to pembrolizumab following durvalumab failure in a patient with microsatellite instability-high cholangiocarcinoma","volume":"16","author":"Sasaki A","year":"2024","unstructured":"Sasaki A, Matsuda K, Okamoto R. Exceptional response to pembrolizumab following durvalumab failure in a patient with microsatellite instability-high cholangiocarcinoma. Cureus. 2024, 16:e75724. 10.7759\/cureus.75724","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13867","article-title":"Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Brito AB","year":"2021","unstructured":"Brito AB, Camandaroba MP, de Lima VC. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer. 2021, 12:1058-66. 10.1111\/1759-7714.13867","journal-title":"Thorac Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02084-y","article-title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy","volume":"128","author":"Wang Y","year":"2023","unstructured":"Wang Y, Du J, Gao Z, et al.. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023, 128:1196-207. 10.1038\/s41416-022-02084-y","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3991","article-title":"Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity","volume":"25","author":"Tanegashima T","year":"2019","unstructured":"Tanegashima T, Togashi Y, Azuma K, et al.. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. Clin Cancer Res. 2019, 25:4808-19. 10.1158\/1078-0432.CCR-18-3991","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette ZY","year":"2017","unstructured":"Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?. Front Immunol. 2017, 8:1597. 10.3389\/fimmu.2017.01597","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley JH","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, et al.. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017, 23:3158-67. 10.1158\/1078-0432.CCR-16-1761","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro B","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, et al.. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024, 35:448-57. 10.1016\/j.annonc.2024.02.005","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2023.11.21","article-title":"Complications of immunotherapy in advanced hepatocellular carcinoma","volume":"24","author":"Song YG","year":"2024","unstructured":"Song YG, Yoo JJ, Kim SG, Kim YS. Complications of immunotherapy in advanced hepatocellular carcinoma. J Liver Cancer. 2024, 24:9-16. 10.17998\/jlc.2023.11.21","journal-title":"J Liver Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104808","article-title":"T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors","volume":"213","author":"Li L","year":"2025","unstructured":"Li L, Huang Y, Xue R, et al.. T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2025, 213:104808. 10.1016\/j.critrevonc.2025.104808","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu A","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J. 2021, 14:2012-22. 10.1093\/ckj\/sfab090","journal-title":"Clin Kidney J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma","volume":"162","author":"Su GL","year":"2022","unstructured":"Su GL, Altayar O, O'Shea R, et al.. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022, 162:920-34. 10.1053\/j.gastro.2021.12.276","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435591-successful-treatment-of-nivolumab-plus-ipilimumab-after-progression-on-durvalumab-plus-tremelimumab-in-advanced-hepatocellular-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T08:01:22Z","timestamp":1763884882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435591-successful-treatment-of-nivolumab-plus-ipilimumab-after-progression-on-durvalumab-plus-tremelimumab-in-advanced-hepatocellular-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.97530","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}